99. Chronic intestinal pseudo-obstruction Clinical trials / Disease details
Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04118699 (ClinicalTrials.gov) | December 25, 2019 | 23/9/2019 | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial | Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial | Chronic Intestinal Pseudo-obstruction | Drug: Rifaximin oral tablet;Drug: Placebo oral tablet | Yokohama City University | ASKA Pharmaceutical Co., Ltd. | Active, not recruiting | 20 Years | 74 Years | All | 12 | Phase 2 | Japan |